Literature DB >> 14704659

Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients.

N L Lewis1, M Mullaney, K F Mangan, T Klumpp, A Rogatko, D Broccoli.   

Abstract

This study was conducted to determine if the accelerated telomere attrition that occurs as a consequence of allogeneic stem cell transplantation leads to measurable functional defects. Telomere lengths in mononuclear leukocytes obtained from 15 long-term allogeneic stem cell transplant recipients and their respective donors were determined by Southern hybridization and densitometric analysis. Functional assays evaluated the ability of these cells to proliferate in response to a mitogenic stimulus and to differentiate under appropriate cytokine stimulation. Lymphocyte proliferation in response to phytohemagglutinin was determined by measurement of (3)[H]thymidine uptake. The ability of circulating myeloid cells to differentiate was determined after incubation of peripheral blood mononuclear cells with IL-3 and GM-CSF. A total of 13 patients demonstrated telomeric loss, ranging from 0.1 to 3.7 kbp. Strikingly, lymphocytes from 14 of the 15 patients demonstrated a significant decrease in proliferation when compared to their respective donors (68%+/-22, P=0.001). All patients demonstrated at least a 50% decrease in the number of myeloid colony-forming units when compared to their respective donors (P<0.0001). A decreased ability of hematopoietic cells to proliferate and differentiate is phenotypically consistent with an aged immune system. This may correlate with diminished clinically relevant immune responses to infection or vaccination, as seen in the elderly.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14704659     DOI: 10.1038/sj.bmt.1704300

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

Review 1.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

Review 2.  Telomerase and the aging process.

Authors:  Peter J Hornsby
Journal:  Exp Gerontol       Date:  2007-03-30       Impact factor: 4.032

3.  Probing the mitotic history and developmental stage of hematopoietic cells using single telomere length analysis (STELA).

Authors:  Mark Hills; Kai Lücke; Elizabeth A Chavez; Connie J Eaves; Peter M Lansdorp
Journal:  Blood       Date:  2009-04-09       Impact factor: 22.113

Review 4.  Telomeres, atherosclerosis, and the hemothelium: the longer view.

Authors:  Abraham Aviv; Daniel Levy
Journal:  Annu Rev Med       Date:  2011-10-17       Impact factor: 13.739

Review 5.  Frailty and aging in cancer survivors.

Authors:  Kirsten K Ness; Matthew D Wogksch
Journal:  Transl Res       Date:  2020-05-01       Impact factor: 7.012

6.  Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients.

Authors:  Samuel Golpanian; Jill El-Khorazaty; Adam Mendizabal; Darcy L DiFede; Viky Y Suncion; Vasileios Karantalis; Joel E Fishman; Eduard Ghersin; Wayne Balkan; Joshua M Hare
Journal:  J Am Coll Cardiol       Date:  2015-01-20       Impact factor: 24.094

7.  Chemotherapy and Stem Cell Transplantation Increase p16INK4a Expression, a Biomarker of T-cell Aging.

Authors:  William A Wood; Janakiraman Krishnamurthy; Natalia Mitin; Chad Torrice; Joel S Parker; Anna C Snavely; Thomas C Shea; Jonathan S Serody; Norman E Sharpless
Journal:  EBioMedicine       Date:  2016-08-21       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.